Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
The most potent compounds within the
2023-12-07
The most potent compounds within the current series of compounds were therefore , , , , and , with egfr inhibitor possessing the best selectivity towards the lyase reaction in comparison to the hydroxylase reaction, indeed, this compound was found to possess an IC value of 1210nM against the 17α-
-
br Patients and Methods br
2023-12-07
Patients and Methods Results Discussion Gjerdrum et al showed that Axl b 35 is required to maintain the mesenchymal-like invasiveness of metastatic breast carcinoma cells, but Axl knockdown has no effect on the cell proliferation of MDA-MB-231 cells. Mackiewicz et al also showed that down-r
-
In addition to the data provided by the
2023-12-07
In addition to the data provided by the Ki16425 treatment in the K/BxN arthritis model, new findings from the study of two new LPA receptor antagonists confirm the involvement of the LPA pathway in the pathogenesis of experimental arthritis. In the study by Miyabe et al., the authors reported the tr
-
fda approved australia PF also a dual Aurora A
2023-12-07
PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly fda approved australia for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-day schedule the
-
Although the interactions of PhLP with
2023-12-07
Although the interactions of PhLP with Gβγ and its other partners have been convincingly documented through in vitro studies, it is not clear how PhLP controls coelenterazine australia signaling in vivo. C. elegans provides a powerful genetic model to analyze Phosducin function and study its interac
-
Here we provide evidence that NO contributes to
2023-12-06
Here, we provide evidence that NO contributes to changes in synaptic strength, but also offer an explanation as to why previous attempts to link NO to LTP have often failed. Our results describe a model by which cycling AMPARs, held in intracellular pools, are rapidly delivered to the membrane surfa
-
In hypothalamus as indicated in Fig
2023-12-06
In hypothalamus, as indicated in Fig. 2 (column A) and following the enzymatic cascade represented in Fig. 1, we could hypothesize a predominance of Ang 2–10 and Ang III formation in SHR compared to WKY. This is in agreement with previous results that reported significant higher rate of Ang 2–10 for
-
Clinical observations of individuals with a decrease in LOX
2023-12-06
Clinical observations of individuals with a decrease in 12-LOX ABH mg are consistent with 12-LOX potentiating platelet activation and thrombus formation [40]. However, the relative contribution of 12-LOX to these complex disorders cannot be fully elucidated in the absence of a biochemical assessmen
-
In this paper we describe the formation of a structure
2023-12-06
In this paper, we describe the formation of a structure-based pharmacophore which lead to the discovery of several hydrophobic, yet non-lipid inhibitors of ATX. These compounds docked within the same volume occupied by the initial non-lipid inhibitors of ATX used to build the pharmacophore. Violatio
-
Materials and methods br Results br Discussion ATX plays
2023-12-06
Materials and methods Results Discussion ATX plays a significant role in initiating and sustaining tumor metastasis [43]. LPA stimulates cell proliferation, migration and survival by acting on its cognate G-protein-coupled receptors. Aberrant LPA production, receptor Schisandrol B and signali
-
br Acknowledgments This study is a part of a MSc
2023-12-05
Acknowledgments This study is a part of a MSc thesis and supported by Scientific Research Projects Coordination Unit of Akdeniz University (grant number: 2011.02.0122.007). Introduction Apelin receptor (putative receptor protein related to the angiotensin receptor AT1, APJ) belongs to the G-p
-
ap4 br Funding This work was supported by the National Natur
2023-12-05
Funding This work was supported by the National Natural Science Foundation of China (grant No. 81573664). Thanks to Jing-xian Yang from the Pharmacology Laboratory of Liaoning University of Traditional Chinese Medicine for support with technology and experimental equipment. Disclosure Confl
-
Based on the general structure function principle in biology
2023-12-05
Based on the general structure-function principle in biology [[19], [20], [21]], toxic oligomers are expected to have well-defined three-dimensional structures to carry out their pathological functions. A common amyloid toxicity mechanism also suggests that toxic oligomers of different amyloid prote
-
Our previous study showed that TRIM could target
2023-12-05
Our previous study showed that TRIM31 could target TSC1-TSC2 complex and contributed to the clinical cancer progression [6]. In this study, we showed that TRIM31 could directly target p53 for ubiquitous degradation and further mediated anoikis-resistance of HCC cells. To further clarify the role of
-
Outro grupo de trabalho analisou pares de
2023-12-05
Outro grupo de trabalho analisou 8.503 pares de gêmeos dinamarqueses de meia‐idade (nos inhibitor of apoptosis proteins de cognição comparados com os que não sofreram qualquer intervenção, no entanto os autores consideram a diferença como um efeito de tamanho negligenciável. Na análise intrapares o
16338 records 225/1090 page Previous Next First page 上5页 221222223224225 下5页 Last page